Inclusion Criteria
Study participants must have biopsy-proven psoriasis with 3 distinct psoriatic lesions. (Biopsy-proven Reiter's syndrome patients with 3 distinct cutaneous lesions may be included.) Documented HIV antibody (by federally licensed ELISA test) positive patients.
Prior Medication:
Allowed:
Exclusion Criteria
Co-existing Condition:
Patients with the following are excluded:
- Presence of any active opportunistic infection.
- Presence of any AIDS-defining neoplasms (excluding Kaposi's sarcoma) such as central nervous system (CNS) lymphoma.
- Known hypersensitivity to zidovudine (AZT).
- Impaired renal function.
- Significant hepatic dysfunction.
Concurrent Medication:
Excluded:
- Topical steroid, anthralin, or tar preparations. Etretinate, methotrexate, or psoralen ultraviolet A (PUVA) therapy. Psoriatic treatment such as systemic agents or topical steroids (emollients used distal to the control lesions and antipruritic shampoos are admissible).
Patients with the following are excluded:
- Presence of any active opportunistic infection.
- Presence of any AIDS-defining neoplasms (excluding Kaposi's sarcoma) such as central nervous system (CNS) lymphoma.
- Known hypersensitivity to zidovudine (AZT).
- Impaired renal function.
- Significant hepatic dysfunction.
Prior Medication:
Excluded:
- Other antiretroviral agents (e.g., suramin, ribavirin, HPA-23, dideoxycytidine).
- Excluded within 2 weeks of study entry:
- Topical steroid, anthralin, or tar preparations.
- Any other experimental therapy drugs which cause significant bone marrow suppression such as antifolates or pyrimethamine.
- Cytolytic chemotherapy.
- Drugs which cause significant nephrotoxicity or hepatotoxicity.
- Rifampin or rifampin derivatives.
- Excluded within 4 weeks of study entry:
- Etretinate, methotrexate, or psoralen ultraviolet A (PUVA) therapy.
- Excluded within 8 weeks of study entry:
- Immunomodulating agents, including steroids, interferon, Isoprinosine, and interleukin 2.
Purpose
